Literature DB >> 21130408

Epigenetics in AML.

Ari M Melnick1.   

Abstract

Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML). These signatures reflect leukemic mechanisms and have clinical and prognostic significance. Compared with genetic lesions in AML, epigenetic lesions appear to be more frequent and recurrent.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh：

Year:  2010        PMID： 21130408     DOI： 10.1016/j.beha.2010.09.017

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  15 in total

1.  Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.

Authors:  Mark P Chao; Andrew J Gentles; Susmita Chatterjee; Feng Lan; Andreas Reinisch; M Ryan Corces; Seethu Xavy; Jinfeng Shen; Daniel Haag; Soham Chanda; Rahul Sinha; Rachel M Morganti; Toshinobu Nishimura; Mohamed Ameen; Haodi Wu; Marius Wernig; Joseph C Wu; Ravindra Majeti
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

2.  An ATRActive future for differentiation therapy in AML.

Authors:  Daniel E Johnson; Robert L Redner
Journal:  Blood Rev       Date:  2015-01-21       Impact factor: 8.250

3.  Aberrant DNA methylation of acute myeloid leukemia and colorectal cancer in a Chinese pedigree with a MLL3 germline mutation.

Authors:  Fuhua Yang; Qiang Gong; Wentao Shi; Yunding Zou; Jingmin Shi; Fengjiang Wei; Qingrong Li; Jieping Chen; Wei-Dong Li
Journal:  Tumour Biol       Date:  2016-07-12

4.  MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia.

Authors:  Jun Qian; Qin Chen; Dong-Ming Yao; Lei Yang; Jing Yang; Xiang-Mei Wen; Ying-Ying Zhang; Hai-Yan Chai; Ji-Chun Ma; Zhao-Qun Deng; Jiang Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.

Authors:  Jonathan E Sandoval; Yung-Hsin Huang; Abigail Muise; Margaret A Goodell; Norbert O Reich
Journal:  J Biol Chem       Date:  2019-01-31       Impact factor: 5.157

Review 6.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

7.  Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes.

Authors:  Joyce R Vido; Randall L Adam; Irene G H Lorand-Metze; Konradin Metze
Journal:  Diagn Pathol       Date:  2011-09-29       Impact factor: 2.644

8.  A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.

Authors:  Weili Sun; Timothy Triche; Jemily Malvar; Paul Gaynon; Richard Sposto; Xiaojing Yang; Henrique Bittencourt; Andrew E Place; Yoav Messinger; Chris Fraser; Luciano Dalla-Pozza; Bodour Salhia; Peter Jones; Alan S Wayne; Lia Gore; Todd M Cooper; Gangning Liang
Journal:  Blood       Date:  2018-01-16       Impact factor: 25.476

9.  Molecular characteristics and chromatin texture features in acute promyelocytic leukemia.

Authors:  Mariana R B De Mello; Dulcineia M Albuquerque; Fernanda Gonçalves Pereira-Cunha; Krizzia B Albanez; Katia B B Pagnano; Fernando F Costa; Konradin Metze; Irene Lorand-Metze
Journal:  Diagn Pathol       Date:  2012-06-28       Impact factor: 2.644

10.  Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.

Authors:  Hanne Fredly; Bjørn Tore Gjertsen; Oystein Bruserud
Journal:  Clin Epigenetics       Date:  2013-07-30       Impact factor: 6.551
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.